AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Tenaya Therapeutics shares surge 14.34% after-hours as positive clinical data and DSMB support advance gene therapy trials.
ByAinvest
Monday, Nov 10, 2025 4:14 pm ET1min read
Tenaya Therapeutics surged 14.34% in after-hours trading following the release of third-quarter 2025 financial results and clinical updates. The company reported positive interim data from its MyPEAK-1 trial for TN-201 gene therapy, including durable, dose-dependent MyBP-C protein increases and improved hypertrophy measures in MYBPC3-associated HCM patients. The Data Safety Monitoring Board endorsed dose expansion for both TN-201 and TN-401 programs, while the RIDGE-1 trial for TN-401 reached key dosing milestones. Additionally, reduced R&D and G&A expenses, coupled with a $56.3M cash balance sufficient for operations through mid-2026, reinforced investor confidence. These developments, highlighting therapeutic progress and financial discipline, directly drove the post-market rally.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet